Sort
15,273 grants matching “antimicrobial resistance”
An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2021 · AI
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo
$1,000,000Allen R. Comer · Stratatech Corporation · R44 · FY2011 · AI
Direct detection and identification of antimicrobial resistance genes in bloodstream infections
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2024 · AI
Near patient molecular diagnostics test for infections
$1,000,000Vincent Jen-Jr Gau · Genefluidics, Inc. · SB1 · FY2018 · AI
Massively Multiplexed dsDNA Invasion Arrays
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2021 · AI
A Culture-Free Platform for Rapid Fungal Pathogen Identification
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2020 · AI
Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool
$1,000,000Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2021 · AI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib
$1,000,000Richard W Scott · Fox Chase Chemical Diversity Center, Inc · R44 · FY2013 · AI
An automated platform for direct-from-specimen identification of pathogens common in endocarditis
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2019 · AI
HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating
$1,000,000Buket Demir · Halomine, Inc. · R44 · FY2023 · AI
Antibiotics for Recalcitrant Infection
$1,000,000Kenneth Coleman · Arietis · R44 · FY2017 · AI
Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis
$1,000,000Yow-Pin Lim · Prothera Biologics, Llc · R44 · FY2019 · AI
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
$1,000,000Christopher John Burns · Venatorx Pharmaceuticals, Inc. · R44 · FY2019 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis
$1,000,000Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R44 · FY2022 · AI
A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection
$1,000,000Patrick Hennessey · Covira Surgical · R42 · FY2025 · AI
An automated platform for direct-from-specimen identification of pathogens common in endocarditis
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2021 · AI
NSF-RISE: Enhancement of Research and Educational Infrastructure in Nanobiomaterials Science and Engineering at Tuskegee University
$1,000,000Vijaya K Rangari · Tuskegee University · · FY2015 · EDU
Epicenters III: Translational Research to Prevent Healthcare Associated Infection
$1,000,000Richard Platt · Harvard Pilgrim Health Care, Inc. · U54 · FY2015 · CK
An automated culture-free system for the identification of bloodstream infections direct from blood
$1,000,000Alon Singer · Helixbind, Inc. · R44 · FY2024 · AI
Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood
$1,000,000Alon Singer · Helixbind, Inc. · SB1 · FY2023 · AI
Narrow-spectrum Agents Acting against Helicobacter pylori
$1,000,000Kenneth Coleman · Arietis · R44 · FY2015 · AI
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections
$1,000,000Terry Roemer · Prokaryotics, Inc. · R44 · FY2022 · AI
Narrow-spectrum Agents Acting against Helicobacter pylori
$1,000,000Kenneth Coleman · Arietis · R44 · FY2014 · AI
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections
$1,000,000Terry Roemer · Prokaryotics, Inc. · R44 · FY2021 · AI
An automated, scalable, and rapid AST system for Gonorrhea STIs
$1,000,000Roy R Swiger · Acenxion Biosystems, Inc. · R44 · FY2023 · AI